127 related articles for article (PubMed ID: 10803640)
1. Safety of moxidectin in avermectin-sensitive collies.
Paul AJ; Tranquilli WJ; Hutchens DE
Am J Vet Res; 2000 May; 61(5):482-3. PubMed ID: 10803640
[TBL] [Abstract][Full Text] [Related]
2. Assessment of toxicosis induced by high-dose administration of milbemycin oxime in collies.
Tranquilli WJ; Paul AJ; Todd KS
Am J Vet Res; 1991 Jul; 52(7):1170-2. PubMed ID: 1892275
[TBL] [Abstract][Full Text] [Related]
3. Safety of selamectin in dogs.
Novotny MJ; Krautmann MJ; Ehrhart JC; Godin CS; Evans EI; McCall JW; Sun F; Rowan TG; Jernigan AD
Vet Parasitol; 2000 Aug; 91(3-4):377-91. PubMed ID: 10940536
[TBL] [Abstract][Full Text] [Related]
4. Dermal safety study with imidacloprid/moxidectin topical solution in the ivermectin-sensitive collie.
Paul AJ; Hutchens DE; Firkins LD; Borgstrom M
Vet Parasitol; 2004 May; 121(3-4):285-91. PubMed ID: 15135868
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation.
Sherman JG; Paul AJ; Firkins LD
Am J Vet Res; 2010 Jan; 71(1):115-9. PubMed ID: 20043790
[TBL] [Abstract][Full Text] [Related]
6. Effects of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies.
Paul AJ; Hutchens DE; Firkins LD; Keehan CM
Am J Vet Res; 2004 Mar; 65(3):277-8. PubMed ID: 15027671
[TBL] [Abstract][Full Text] [Related]
7. Safety of an extended-release injectable moxidectin suspension formulation (ProHeart
Krautmann MJ; Mahabir S; Fielder A; Collard W; Wolthuis TL; Esch K; Morton T; Alleman K; Luo L; McCandless E; Nederveld S; Kryda K; Carroll R; Boucher JF
Parasit Vectors; 2019 Sep; 12(1):433. PubMed ID: 31492168
[TBL] [Abstract][Full Text] [Related]
8. Faecal excretion profile of moxidectin and ivermectin after oral administration in horses.
Pérez R; Cabezas I; Sutra JF; Galtier P; Alvinerie M
Vet J; 2001 Jan; 161(1):85-92. PubMed ID: 11145833
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive Collies.
Fassler PE; Tranquilli WJ; Paul AJ; Soll MD; DiPietro JA; Todd KS
J Am Vet Med Assoc; 1991 Aug; 199(4):457-60. PubMed ID: 1917657
[TBL] [Abstract][Full Text] [Related]
10. Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of collies from the northwestern United States.
Mealey KL; Bentjen SA; Waiting DK
Am J Vet Res; 2002 Apr; 63(4):479-81. PubMed ID: 11939306
[TBL] [Abstract][Full Text] [Related]
11. Clinical observations in collies given ivermectin orally.
Paul AJ; Tranquilli WJ; Seward RL; Todd KS; DiPietro JA
Am J Vet Res; 1987 Apr; 48(4):684-5. PubMed ID: 3592367
[TBL] [Abstract][Full Text] [Related]
12. Comparison of moxidectin oral gel and ivermectin oral paste against a spectrum of internal parasites of ponies with special attention to encysted cyathostome larvae.
Monahan CM; Chapman MR; Taylor HW; French DD; Klei TR
Vet Parasitol; 1996 Jun; 63(3-4):225-35. PubMed ID: 8966989
[TBL] [Abstract][Full Text] [Related]
13. Mutual resistance to avermectins and milbemycins: oral activity of ivermectin and moxidectin against ivermectin-resistant and susceptible nematodes.
Shoop WL; Haines HW; Michael BF; Eary CH
Vet Rec; 1993 Oct; 133(18):445-7. PubMed ID: 8291174
[TBL] [Abstract][Full Text] [Related]
14. Ivermectin toxicity in 17 collies.
Hopper K; Aldrich J; Haskins SC
J Vet Intern Med; 2002; 16(1):89-94. PubMed ID: 11822811
[TBL] [Abstract][Full Text] [Related]
15. Safety of selamectin in cats.
Krautmann MJ; Novotny MJ; De Keulenaer K; Godin CS; Evans EI; McCall JW; Wang C; Rowan TG; Jernigan AD
Vet Parasitol; 2000 Aug; 91(3-4):393-403. PubMed ID: 10940537
[TBL] [Abstract][Full Text] [Related]
16. Full season efficacy of moxidectin microsphere sustained release formulation for the prevention of heartworm (Dirofilaria immitis) infection in dogs.
Genchi C; Rossi L; Cardini G; Kramer LH; Venco L; Casiraghi M; Genchi M; Agostini A
Vet Parasitol; 2002 Dec; 110(1-2):85-91. PubMed ID: 12446092
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of an injectable, sustained-release formulation of moxidectin in preventing experimental heartworm infection in mongrel dogs challenged 12 months after administration.
Lok JB; Knight DH; Nolan TJ; Grubbs ST; Cleale RM; Heaney K
Vet Parasitol; 2005 Mar; 128(1-2):129-35. PubMed ID: 15725542
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of selamectin in the prevention of adult heartworm (Dirofilaria immitis) infection in dogs in northern Italy.
Clemence RG; Sarasola P; Genchi C; Smith DG; Shanks DJ; Jernigan AD; Rowan TG
Vet Parasitol; 2000 Aug; 91(3-4):251-8. PubMed ID: 10940526
[TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics and faecal excretion of ivermectin, doramectin and moxidectin following oral administration in horses.
Gokbulut C; Nolan AM; McKellar QA
Equine Vet J; 2001 Sep; 33(5):494-8. PubMed ID: 11558745
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxic effects of ivermectin administration in genetically engineered mice with targeted insertion of the mutated canine ABCB1 gene.
Orzechowski KL; Swain MD; Robl MG; Tinaza CA; Swaim HL; Jones YL; Myers MJ; Yancy HF
Am J Vet Res; 2012 Sep; 73(9):1477-84. PubMed ID: 22924731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
